Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy
| Autor: | Hirotaka Nagamatsu, Jun Teishima, Kenichiro Ikeda, Kohei Kobatake, Yasuyuki Seno, Akio Matsubara, Keisuke Hieda, Koichi Shoji, Shinya Ohara, Mitsuru Kajiwara, Tetsutaro Hayashi, Shogo Inoue, Katsutoshi Miyamoto, Kanao Kobayashi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
renal cell carcinoma
Cancer Research medicine.medical_specialty Pathology Multivariate analysis Oncogene biology business.industry medicine.medical_treatment Hazard ratio C-reactive protein Cancer Articles medicine.disease Molecular medicine Gastroenterology Targeted therapy Oncology Renal cell carcinoma Internal medicine medicine biology.protein prognostic factor business |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2014.2207 |
| Popis: | The present study aimed to investigate the impact of pre-treatment C-reactive protein (CRP) levels on the prediction of prognosis in patients with metastatic renal cell carcinoma (mRCC), who were classified as intermediate-risk patients using the Memorial Sloan Kettering Cancer Center (MSKCC) risk classification and who received molecular targeted therapy. The oncological outcome of 140 patients with mRCC who underwent molecular targeted therapy was analyzed. Patients were divided into favorable-, intermediate- and poor-risk groups (groups F, I and P, respectively) based on the MSKCC risk classification. The patients in group I were then further classified into two groups based on pre-treatment serum CRP levels. The overall survival (OS) rates of the patients in these groups were then assessed. The OS rate of the patients in group I with normal pre-treatment CRP levels was found to be significantly increased compared with that of patients with high pre-treatment CRP levels (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|